Concourse Financial Group Securities, Inc. Evaxion Biotech A/S Transaction History

Concourse Financial Group Securities, Inc.

$1.64 Billion
Q3 2024

13 transactions

Quarter	Operation	Price Per share
Q4 2023 Feb 07, 2024	BUY	$0.6 - $1.17 $0 - $0
Q3 2023 Oct 30, 2023	BUY	$0.48 - $1.33 $0 - $0
Q3 2023 Oct 25, 2023	BUY	$0.48 - $1.33 $0 - $0
Q2 2023 Aug 10, 2023	BUY	$1.12 - $1.74 $0 - $0
Q1 2023 May 15, 2023	BUY	$1.03 - $1.8 $0 - $0
Q4 2022 Jan 30, 2023	BUY	$1.7 - $30.2 $0 - $0
Q3 2022 Nov 15, 2022	BUY	$1.9 - $27.7 $0 - $0
Q2 2022 Aug 09, 2022	BUY	$1.6 - $3.07 $0 - $0
Q1 2022 May 09, 2022	BUY	$2.66 - $4.65 $0 - $0
Q4 2021 Feb 07, 2022	BUY	$4.0 - $12.68 $0 - $0
Q3 2021 Nov 09, 2021	BUY	$5.32 - $9.65 $0 - $0
Q2 2021 Aug 13, 2021	BUY	$5.2 - $7.94 $0 - $0
Q1 2021 May 13, 2021	BUY	$5.3 - $9.95 $0 - $0

Others Institutions Holding EVAX

# of Institutions

Shares Held

37.5K

Call Options Held

Put Options Held

Telemetry Investments, L.L.C. New York, NY

37.5K
Shares

$31,875
0.11% of portfolio

View Full List

About Evaxion Biotech A/S

Ticker EVAX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 23,977,900
Market Cap $20.4M
Description
Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Ph...

More about EVAX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Concourse Financial Group Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Concourse Financial Group Securities, Inc. with notifications on news.

Account